blue-overlay
blue-overlay

Press Releases

October 11, 2016

FORMA THERAPEUTICS APPOINTS JIM WINKLER, PH.D., VICE PRESIDENT, DISCOVERY AND TRANSLATIONAL BIOLOGY

WATERTOWN, Mass. — October 11, 2016 — FORMA Therapeutics, a clinical-stage and fully integrated research and development company, today announced the appointment of Jim Winkler,…

August 31, 2016

FORMA THERAPEUTICS ACHIEVES CLINICAL CANDIDATE LICENSING MILESTONE FOR NASH COMPOUND IN STRATEGIC ALLIANCE WITH CELGENE CORPORATION

FORMA Therapeutics delivers second Phase I-ready compound under Celgene alliance WATERTOWN, Mass. – August 31, 2016 – FORMA Therapeutics (FORMA) announced today that they have…

August 29, 2016

FORMA THERAPEUTICS APPOINTS KAROLINE SHAIR, Ph.D., J.D., VICE PRESIDENT, LEGAL AND CHIEF INTELLECTUAL PROPERTY COUNSEL

WATERTOWN, Mass. – August 29, 2016 – FORMA Therapeutics, a clinical-stage and fully integrated research and development company, today announced the appointment of Karoline Shair,…

January 12, 2016

FORMA THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 1 STUDY OF FT-1101 IN ADVANCED HEMATOLOGICAL MALIGNANCIES

– The first clinical candidate under FORMA’s 2014 Celgene collaboration, FT-1101, is a structurally distinct pan-BET bromodomain epigenetic modifier – WATERTOWN, Mass. – January 12,…

January 12, 2016

FORMA THERAPEUTICS ACHIEVES AN ADDITIONAL MAJOR OBJECTIVE IN COLLABORATION WITH CELGENE CORPORATION TO ADVANCE INNOVATIVE PROTEIN HOMEOSTASIS DRUGS

WATERTOWN, Mass. – January 12, 2016 – FORMA Therapeutics announced today that it has successfully met a third objective under its strategic collaboration agreement with…

News & Events

September 19, 2017 / CellPress (Publication)

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6

— Maureen Caligiuri; Bingsong Han; David R. Lancia; Xiaozhang Zheng (Cell Reports 20, 2860–2875, September 19, 2017)

July 20, 2017 / ACS Medicinal Chemistry Letters (Publication)

Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains

— Watertown, MA / Dave Millan, Ph.D. (Senior Director, Head of Medicinal Chemistry)

June 2, 2017 / Managing Intellectual Property (Award)

Karoline Shair of FORMA Therapeutics Recognized as a 2017 Corporate IP Star

April 25, 2017 / Drug Discovery Chemistry Conference (Presentation)

Design and Optimization of Novel Benzopiperazines as Potent Inhibitors of BET Bromodomains

— San Diego, CA / Dave Millan, Ph.D. (Senior Director and Head, Medicinal Chemistry)

September 21, 2016 / Discovery on Target (Presentation)

Discovery of Novel Protein Homeostasis Inhibitors Utilizing FORMA’s Drug Discovery Engine

— Boston, MA / Stephanos Ioannidis (Senior Director, Early Portfolio)